A Pilot Study to Assess the Safety and Efficacy of Sarilumab in Halting Progression of Morphea
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Sarilumab (Primary)
- Indications Circumscribed scleroderma
- Focus Therapeutic Use
- 21 Feb 2019 Last checked against ClinicalTrials.gov record.
- 13 Feb 2019 Planned End Date changed from 1 Oct 2019 to 1 Jun 2020.
- 13 Feb 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Jun 2020.